Ireland
--:--IST
Recruiting Phase 2

Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence

NCT07799519 · tracked via the Priya Life Science Taiwan tracker
Phase
Phase 2
Started
2026-06-09
Last updated
2026-09-02

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

Finerenone →

Finerenone: Oral finerenone 10 mg or 20 mg once daily (dose per eGFR, with Week-4 up-titration where applicable based on serum potassium) for 12 months after catheter ablation.

Study summary

Atrial fibrillation (AF) is a common heart rhythm disorder associated with stroke, heart failure, and increased mortality. Catheter ablation with pulmonary vein isolation (PVI) is an effective rhythm-control strategy, but 20-30% of patients experience AF recurrence within one year. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist with anti-inflammatory, antifibrotic, and metabolic effects, was associated with a lower incidence of AF in prior large trials, and preclinical studies suggest it promotes "browning" of adipose tissue and improves epicardial adipose tissue (EAT) characteristics.

This single-center, randomized, investigator-blinded pilot trial will enroll 40 patients undergoing first-time catheter ablation for AF. After successful PVI, participants will be randomized 1:1 to receive finerenone or usual care for 12 months. The primary endpoint is AF recurrence (any atrial arrhythmia episode lasting 30 seconds or longer) after a 90-day blanking period, within 12 months post-ablation. Mechanistic endpoints include EAT remodeling assessed by cardiac computed tomography and echocardiography, and circulating uncoupling protein-1 (UCP1) levels as a biomarker of adipose tissue browning.

The investigators hypothesize that finerenone will lower AF recurrence after ablation, partly through modulation of EAT function.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-80 years * Atrial fibrillation scheduled for first-time catheter ablation (pulmonary vein isolation) * Estimated glomerular filtration rate (eGFR) \>=25 mL/min/1.73 m2 * Serum potassium \<=5.0 mmol/L Exclusion Criteria: * History of prior catheter-based or surgical pulmonary vein isolation * Current use of other mineralocorticoid receptor antagonists (MRAs) * Severe renal impairment (eGFR \<25 mL/min/1.73 m2) * Serum potassium \>5.0 mmol/L * Severe liver disease (Child-Pugh class C) * Known hypersensitivity to the investigational drug * Contraindications to the investigational drug, such as concomitant use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital) * Active cancer or recent chemotherapy * Women who are pregnant, breastfeeding, or planning to become pregnant during the study period

Primary outcome measure(s)

  • Atrial fibrillation recurrence after the blanking period — From day 91 (end of the 90-day blanking period) to 12 months after ablation
    Proportion of participants with any documented atrial arrhythmia episode (AF, atrial flutter, or atrial tachycardia) lasting \>=30 seconds, detected by 24-hour Holter monitoring, 12-lead ECG, or symptom-triggered monitoring, occurring after the 90-day blanking period.

Trial sites (1)

FacilityCityRegionStatus
National Cheng Kung University Hospital Tainan Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07799519 on ClinicalTrials.gov ↗ ← All trials in Taiwan